# Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

> **NCT06175351** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** 9MW1911
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06175351
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-06
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06175351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06175351, "Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06175351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*